entasis
therapeutics
highlights
multiple
data
presentations
virtual
id
week
waltham
globe
newswire
entasis
therapeutics
holdings
nasdaq
ettx
biopharmaceutical
company
focused
discovery
development
novel
antibacterial
products
today
announced
company
multiple
data
presentations
virtual
id
week
held
october
details
poster
presentations
include
active
recent
acinetobacter
baumannii
clinical
isolates
middle
east
session
title
novel
agents
poster
number
presenting
author
alita
miller
head
bioscience
entasis
therapeutics
date
wednesday
october
vitro
activity
recent
global
clinical
acinetobacter
complex
isolates
session
title
novel
agents
poster
number
presenting
author
alita
miller
head
bioscience
entasis
therapeutics
date
wednesday
october
serious
infections
caused
carbapenem
susceptible
carbapenem
resistant
acinetobacter
complex
retrospective
review
session
title
respiratory
infections
bacterial
poster
number
presenting
author
khurram
rana
director
clinical
scientist
entasis
therapeutics
date
wednesday
october
novel
inhibitor
durlobactam
dur
enhance
susceptibility
mdr
mycobacterium
abscessus
mab
session
title
tuberculosis
mycobacterial
infections
poster
number
presenting
author
khalid
dousa
fellow
case
western
reserve
university
date
wednesday
october
poster
abstract
presentations
presented
wednesday
october
entasis
entasis
biopharmaceutical
company
focused
discovery
development
commercialization
novel
antibacterial
products
treat
serious
infections
caused
bacteria
entasis
design
platform
produced
pipeline
product
candidates
including
targeting
acinetobacter
baumannii
infections
zoliflodacin
targeting
neisseria
gonorrhoeae
infections
targeting
enterobacteriaceae
infections
targeting
pseudomonas
infections
information
visit
entasis
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
words
may
expect
plan
anticipate
estimate
intend
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
intended
identify
statements
statements
based
entasis
expectations
assumptions
date
press
release
statements
involves
risks
uncertainties
actual
results
may
differ
materially
statements
many
factors
may
cause
differences
current
expectations
actual
results
including
unexpected
safety
efficacy
data
observed
clinical
studies
clinical
site
activation
rates
clinical
trial
enrollment
rates
lower
expected
changes
expected
existing
competition
changes
regulatory
environment
failure
entasis
collaborators
support
advance
collaborations
product
candidates
unexpected
litigation
disputes
many
factors
beyond
entasis
control
risks
uncertainties
described
fully
entasis
filings
securities
exchange
commission
including
section
titled
risk
factors
contained
therein
statements
contained
announcement
made
date
except
required
law
entasis
assumes
obligation
update
statements
contained
herein
reflect
change
expectations
even
new
information
becomes
available
entasis
company
contact
kyle
dow
entasis
therapeutics
investor
relations
contact
james
salierno
ruth
group
jsalierno
media
contact
kirsten
thomas
ruth
group
kthomas
